<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2338">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 10, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04871698</url>
  </required_header>
  <id_info>
    <org_study_id>R44AG065118</org_study_id>
    <nct_id>NCT04871698</nct_id>
  </id_info>
  <brief_title>On Site Sensors Monitoring Impacts of Cognitive Decline on ADLs</brief_title>
  <official_title>Improved AD/ADRD Assessment Sensitivities Using a Novel In-Situ Sensor System</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute on Aging (NIA)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Texas A&amp;M University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Baylor Research Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Georgia Institute of Technology</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National Institute on Aging (NIA)</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this research is to compare the effectiveness of a continuous monitoring&#xD;
      system to assess Activities of Daily Living (ADLs) over time compared to the traditional&#xD;
      assessments used by medical professionals as Alzheimer's Disease and Alzheimer's Disease&#xD;
      Related Dementias (AD/ADRD) progresses.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 14, 2020</start_date>
  <completion_date type="Anticipated">March 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">March 31, 2022</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>18 Months</target_duration>
  <primary_outcome>
    <measure>Demonstrate equivalency of the proposed IoT system against ADCS-ADL/23 Assessment</measure>
    <time_frame>18 months</time_frame>
    <description>The ADCS-ADL/23 assessment will be utilized to measure changes in activities of daily living in the sample population while BC's system is also in place independently measuring the changes in activities of daily living.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Identify improved sensitivities for detection of early and moderate-stage AD/ADRD activities of daily living changes</measure>
    <time_frame>18 months</time_frame>
    <description>AI techniques will search sensor data for subfactor and novel groupings for statistically significant improvements from what is measured by the ADCS/ADL-23 assessment of decline.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Establish initial data sets and protocols for use of the developed ADL/IADL system data for integration with AD/ADRD research</measure>
    <time_frame>18 months</time_frame>
    <description>Database structures and meta-data will be established for anonymous data sets.</description>
  </secondary_outcome>
  <enrollment type="Anticipated">140</enrollment>
  <condition>Dementia</condition>
  <condition>Dementia Alzheimers</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Adults 65 and older with mild to moderate dementia.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Fluent in English to understand and sign the consent or assent documents.&#xD;
&#xD;
          -  Adult over 65 years of age with no children under 18 years old living in residence.&#xD;
&#xD;
          -  Adult anticipates they will be living primarily at designated residence over next 18&#xD;
             months.&#xD;
&#xD;
          -  Must receive caregiver interaction at least 6 hours/week.&#xD;
&#xD;
          -  Must undergo a Mini-Mental State Exam (MMSE) assessment at baseline during recruitment&#xD;
             as well as at the end of the study with a resulting score of 11-25 as part of the&#xD;
             recruitment phase of the study.&#xD;
&#xD;
          -  Must be willing to have home or facility equipped with sensors to obtain activity and&#xD;
             location data.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        -&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Melissa SoRelle</last_name>
    <phone>254-742-6030</phone>
    <email>melissa.sorelle@birkelandcurrent.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sarah Fitch, MA</last_name>
    <phone>254-742-6034</phone>
    <email>sarah.fitch@birkelandcurrent.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Birkeland Current</name>
      <address>
        <city>Waco</city>
        <state>Texas</state>
        <zip>76704</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melissa SoRelle</last_name>
      <phone>254-742-6030</phone>
      <email>melissa.sorelle@birkelandcurrent.com</email>
    </contact>
    <contact_backup>
      <last_name>Sarah Fitch</last_name>
      <phone>254-742-6034</phone>
      <email>sarah.fitch@birkelandcurrent.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>April 29, 2021</study_first_submitted>
  <study_first_submitted_qc>April 29, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 4, 2021</study_first_posted>
  <last_update_submitted>April 29, 2021</last_update_submitted>
  <last_update_submitted_qc>April 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>National Institute on Aging (NIA)</investigator_affiliation>
    <investigator_full_name>John Fitch</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dementia</mesh_term>
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

